Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 11/20 | 0.44 |
| ▸ | CNR2 | P34972 | 11/20 | 0.44 |
| ▸ | HTR3A | P46098 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25001937 | 0.89 | CNR1 (0.45) | NPC1CNR1CNR2HTR3AATM | |
| SCHEMBL29822064 | 0.89 | CNR2 (0.45) | CNR1CNR2HTR3A | |
| SCHEMBL30168307 | 0.87 | CNR1 (0.46) | CNR1CNR2HTR3AKDM4E | |
| SCHEMBL2982363 | 0.84 | ELANE (0.42) | NPC1CNR1CNR2HTR3A | |
| SCHEMBL21044790 | 0.82 | DGAT1 (0.41) | NPC1CNR1CNR2 | |
| SCHEMBL29748840 | 0.82 | DGAT1 (0.41) | NPC1CNR1CNR2 | |
| SCHEMBL20744082 | 0.81 | NPC1 (0.39) | NPC1 | |
| SCHEMBL30668697 | 0.81 | NPC1 (0.39) | NPC1 | |
| SCHEMBL31050029 | 0.80 | DGAT1 (0.40) | NPC1CNR1CNR2 | |
| SCHEMBL30848403 | 0.80 | NPC1 (0.36) | NPC1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343726-A1 | PYRROLOPYRIDINE-3- AND 4-CARBOXAMIDE COMPOSITIONS AND METHODS FOR CELLULAR PROLIFERATION | THE ROCKEFELLER UNIVERSITY (US) | 2024-10-17 | — | — | US | disclosed |
| WO-2023015156-A1 | PYRROLOPYRIDINE-3- AND 4-CARBOXAMIDE COMPOSITIONS AND METHODS FOR CELLULAR PROLIFERATION | HUDSPETH A JAMES (US) | 2023-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343726-A1 | PYRROLOPYRIDINE-3- AND 4-CARBOXAMIDE COMPOSITIONS AND METHODS FOR CELLULAR PROLIFERATION | LATS1, LATS2, YAP1 | NPC1 4281/4885CNR1 3250/4885CNR2 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.